Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. (Q40419958)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

endometrial carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Athanasios Dimopoulos

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Dimitrios Bafaloukos

2

object named as

Dimitrios Bafaloukos

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Gerassimos Aravantinos

6

object named as

Gerassimos Aravantinos

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Hellenic Co-operative Oncology Group

9

object named as

Hellenic Co-operative Oncology Group

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

Christos A Papadimitriou

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Paris Kosmidis

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

George Fountzilas

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

language of work or name

0 references

publication date

2 May 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

110

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

87-92

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Cancer of the endometrium

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Systemic therapy in metastatic or recurrent endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Treatment modalities in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Taxol is active in platinum-resistant endometrial adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

2 references

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

based on heuristic

inferred from DOI database lookup

Current Status of Taxane and Platinum-Based Chemotherapy in Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Cancer of the ovary

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Paclitaxel and Cisplatin in Advanced or Recurrent Carcinoma of the Endometrium: Long-Term Results of a Phase II Multicenter Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

The calculation of received dose intensity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Sudden Cardiac Death

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.03.004

7 January 2021

Identifiers

10.1016/J.YGYNO.2008.03.004

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18455782%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40419958&oldid=2051699051"